Adjuvant Radiotherapy on Complete Remission Patients
Conditions
Keywords
primary mediastinal lymphoma, radiotherapy, chemotherapy, rituximab
Brief summary
The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP
Interventions
RADIATIONno drugs
Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
Sponsors
Instituto Mexicano del Seguro Social
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Diagnosis of primary mediastinal lymphoma No previous treatment performance status \< 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function
Exclusion criteria
pregnancy \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| measurement of progression free-survival and overall survival at > 5 years | 5 years | Assess if the use of adjuvant radiotherapy improve outcome in patients with primary mediastinal lymphoma treated initially with R-CHOP |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| assess toxicity secondary to mediastinal radiotherapy | > 5 years | Assess if the addition of mediastinal radiotherapy to patients who received anthracyclines can produce an increase in cardiac toxicity |
Countries
Mexico
Outcome results
None listed